Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Investigation Report on China's Omeprazole Market, 2018-2022 - ResearchAndMarkets.com

Research and Markets
Posted on: 02 Nov 18

The "Investigation Report on China's Omeprazole Market, 2018-2022" report has been added to ResearchAndMarkets.com's offering.

The global market size of gastric ulcer drugs exceeded USD 8 billion. In 1988, Swedish company Astra (now known as AstraZeneca) developed a new anti-ulcer drug proton pump inhibitor Omeprazole (trade name: Losec).

Omeprazole, able to inhibit gastric acid secretion and relieve gastralgia, gastrectasia and other symptoms in a short period of time, became popular among ulcer patients immediately after it was marketed. At the end of the 20th century, the annual sales value of Omeprazole once hit a record high of USD 6.26 billion.

Chinese pharmaceutical companies began to imitate Omeprazole API in 1992, after which a large number of generic drugs were put on the market. With the launch of generic Omeprazole in China, Chinese pharmaceutical companies keep scrambling for market share from AstraZeneca. Overall, the market size of Omeprazole in China is growing, with the sales value exceeding CNY 1.3 billion in 2017.

Although there are many anti-ulcer drugs on the market, because of good effects, Omeprazole stands out from its many competitors and secures its leading role. As the lifestyle changes, the number of patients with gastric ulcer continues to rise in China. In the next few years, Omeprazole will still have certain growth potential in China.

Topics Covered:

  • Situation of gastric ulcer in China
  • Sales of Omeprazole in China
  • Competition on China's Omeprazole market
  • Major Omeprazole manufacturers in China
  • Prices of Omeprazole in China
  • Prospect of China's Omeprazole market from 2018 to 2022

Key Topics Covered:

1 Relevant Concepts of Omeprazole

1.1 Indications for Omeprazole

1.2 Development of Omeprazole in China

1.3 Governmental Approval of Omeprazole in China

2 Sales of Omeprazole in China, 2013-2017

2.1 Sales Value of Omeprazole

2.1.1 Overall Sales Value

2.1.2 Sales Value by Region

2.2 Sales Volume of Omeprazole

2.2.1 Overall Sales Volume

2.2.2 Sales Volume by Region

2.3 Sales of Omeprazole by Dosage Form in China, 2013-2017

2.3.1 Tablets

2.3.2 Capsules

2.3.3 Injections

3 Analysis on Major Omeprazole Manufacturers in China, 2013-2017

3.1 Analysis on Market Share of Major Omeprazole Manufacturers

3.1.1 Market Share by Sales Value

3.1.2 Market Share by Sales Volume

3.2 Jiangsu Aosaikang Pharmaceutical Co., Ltd.

3.3 AstraZeneca

3.4 Changzhou Siyao Pharmaceuticals Co., Ltd.

3.5 Zhejiang Jinhua CONBA Bio-pharm. Co., Ltd.

3.6 Hainan Lionco Pharmaceutical Co., Ltd.

4 Prices of Omeprazole in China, 2017-2018

4.1 Jiangsu Aosaikang Pharmaceutical Co., Ltd. (Aoyiming)

4.2 AstraZeneca (Losec)

4.3 Changzhou Siyao Pharmaceuticals Co., Ltd. (Aoke)

4.4 Zhejiang Jinhua CONBA Bio-pharm. Co., Ltd. (KIN-KONG)

4.5 Hainan Lionco Pharmaceutical Co., Ltd. (Ruiboqi)

5 Prospect of China's Omeprazole Market, 2018-2022

5.1 Forecast on Market Size

5.2 Forecast on Market Trend

For more information about this report visit https://www.researchandmarkets.com/research/8nsj4s/investigation?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20181102005209/en/

Business Wire
www.businesswire.com

Last updated on: 02/11/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.